title: Children's clinical cancer trials: what needs to change to allow children access to new cancer drugs?
abstract: Despite numerous advances with the incorporation of multimodal treatment, children with cancers have a major unmet need to access new drugs. Still, a reduced number of new targeted drugs is evaluated in pediatric patients and very few of them progress into late phase trials and clinical use. Changes required include: increased collaboration between all stakeholders, improved understanding of disease biology and its incorporation into early clinical trials, faster and more efficient early and late clinical trials, better incentives for pharmaceutical companies and improving access to new drugs across the globe.
authors: a 1 CNIO-HNJ Clinical Trials Unit, Hospital Niño Jesús , Madrid, Spain.|b 2 Instituto de Investigación Sanitaria La Princesa , Madrid, Spain.|c 3 Division of Clinical Studies, The Institute of Cancer Research , London, UK.|d 4 Paediatric Drug Development, Children and Young People's Unit, The Royal Marsden NHS Foundation Trust , Sutton, UK.
authors: Lucas
authors: L
authors: Moreno
authors: c 3 Division of Clinical Studies, The Institute of Cancer Research , London, UK.|d 4 Paediatric Drug Development, Children and Young People's Unit, The Royal Marsden NHS Foundation Trust , Sutton, UK.
authors: Andrew D J
authors: AD
authors: Pearson
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000600:supply & distribution / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic / Q000379:methods*; D003299:Cooperative Behavior; D004345:Drug Industry / Q000458:organization & administration; D006297:Health Services Accessibility; D006301:Health Services Needs and Demand; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents
keywords: Phase I; childhood cancer; children; clinical trials; drug development; pediatric medicines; targeted drugs